Interim analysis supports long-term safety of nintedanib in the treatment of systemic sclerosis-associated interstitial lung disease

An interim analysis of the SENSCIS-ON open-label extension trial shows the safety profile was consistent with that reported in the SENSCIC trial, with diarrhoea the most frequently reported adverse event. Average change in FVC was also similar (-51.3mL versus -42.7mL in SENSCIS).

Source:

Biospace Inc.